<DOC>
	<DOCNO>NCT02035215</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination therapy omega-3-acids ethylesters 90/Atorvastatin calcium type Ⅱb hyperlipidemia</brief_summary>
	<brief_title>Phase 3 Study Evaluate Efficacy Safety Omega-3-acids Ethylesters 90 Type Ⅱb Hyperlipidemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Hyperlipidemia , Familial Combined</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>LDL≥160mg/dl , 200mg/dl≤TG &lt; 500mg/dl In case smoker , agree smokefree In case woman childbearing age , urine pregnancy test must negative Patients acute artery disease within 3 month History revascularization procedure aneurism operation within 6months Patients myopathy , rhabdomyolysis Patients pancreatitis Patients HIV positive History malignant tumor within 2 year Patients must treat medication prohibit concomitant use study period Patients uncontrolled hypertension ( SBP &gt; 180mmHg DBP &gt; 110mmHg ) Serum Creatinine &gt; 1.2mg/dl ( female ) , &gt; 1.4mg/dl ( male ) AST ALT &gt; 2X ULN CPK &gt; 2X ULN Patients galactose intolerance Lapp lactase deficiency , glucosegalactose malabsorption Allergy Hypersensitive investigational drug History drug alcohol abuse within 2 year In case smoker , intend non smoke Women pregnant , breastfeed Patients treat investigational drug within 1 month time consent obtain Not eligible participate study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Hyperlipidemia , Familial Combined</keyword>
	<keyword>Omega 3 acid ethylesters 90</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>